Inhibition of the AMP-activated protein kinase-α2 accentuates agonist-induced vascular smooth muscle contraction and high blood pressure in mice

Hypertension

Volumn 57, Issue 5, 2011, Pages 1010-1017

  Wang, Shuangxi ^a   Liang, Bin ^a   Viollet, Benoit ^b,c   Zou, Ming Hui ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b INSTITUT COCHIN   (France)

^c INSERM   (France)

Author keywords

AMPK; blood pressure; p190 GAP; Rho A; ROCK

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA2; MYOSIN LIGHT CHAIN; MYOSIN PHOSPHATASE TARGETING SUBUNIT 1; PHENYLEPHRINE; PROTEIN P190; PROTEIN SUBUNIT; RAS PROTEIN; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; AORTA CONSTRICTION; AORTA MEDIA; ARTERY CONSTRICTION; ARTERY MUSCLE; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME REPRESSION; EX VIVO STUDY; GENE SILENCING; HUMAN; HUMAN CELL; MALE; MESENTERIC ARTERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; VASOCONSTRICTION;

AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BLOOD PRESSURE; BLOTTING, WESTERN; CELLS, CULTURED; HUMANS; MICE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; MYOSIN LIGHT CHAINS; MYOSIN-LIGHT-CHAIN PHOSPHATASE; PHOSPHORYLATION; RIBONUCLEOTIDES;

EID: 79955473884     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.168906     Document Type: Article

References (34)

1. Lee-Young RS, Griffee SR, Lynes SE, Bracy DP, Ayala JE, McGuinness OP, Wasserman DH. Skeletal muscle AMP-activated protein kinase is essential for the metabolic response to exercise in vivo. J Biol Chem. 2009;284:23925-23934.
2. Kemp BE, Stapleton D, Campbell DJ, Chen ZP, Murthy S, Walter M, Gupta A, Adams JJ, Katsis F, van Denderen B, Jennings IG, Iseli T, Michell BJ, Witters LA. AMP-activated protein kinase, super metabolic regulator. Biochem Soc Trans. 2003;31:162-168. (Pubitemid 36241420)
3. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, Cantley LC. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA. 2004;101:3329-3335. (Pubitemid 38338195)
4. Hawley SA, Selbert MA, Goldstein EG, Edelman AM, Carling D, Hardie DG. 5'-AMP activates the AMP-activated protein kinase cascade, and Ca2+/calmodulin activates the calmodulin-dependent protein kinase I cascade, via three independent mechanisms. J Biol Chem. 1995;270: 27186-27191.
5. Hardie DG. The AM P-activated protein kinase pathway-new players upstream and downstream. J Cell Sci. 2004;117:5479-5487. (Pubitemid 40012195)
6. Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol. 1999;277: E1-E10. (Pubitemid 29356721)
7. Dong Y, Zhang M, Wang S, Liang B, Zhao Z, Liu C, Wu M, Choi HC, Lyons TJ, Zou MH. Activation of AMP-activated protein kinase inhibits oxidized LDL-triggered endoplasmic reticulum stress in vivo. Diabetes. 59:1386-1396.
8. Dong Y, Zhang M, Liang B, Xie Z, Zhao Z, Asfa S, Choi HC, Zou MH. Reduction of AMP-activated protein kinase α2 increases endoplasmic reticulum stress and atherosclerosis in vivo. Circulation. 121:792-803.
9. Wang S, Zhang M, Liang B, Xu J, Xie Z, Liu C, Viollet B, Yan D, Zou MH. AMPKα2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes. Circ Res. 2009;106:1117-1128.
10. Wang S, Xu J, Song P, Viollet B, Zou MH. In vivo activation of AMP-activated protein kinase attenuates diabetes-enhanced degradation of GTP cyclohydrolase I. Diabetes. 2009;58:1893-1901.
11. Buhl ES, Jessen N, Pold R, Ledet T, Flyvbjerg A, Pedersen SB, Pedersen O, Schmitz O, Lund S. Long-term AICAR administration reduces meta-bolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes. 2002;51:2199-2206. (Pubitemid 34729025)
12. Rivera L, Moron R, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol. 2009;77:1053-1063.
13. Haas E, Bhattacharya I, Brailoiu E, Damjanovic M, Brailoiu GC, Gao X, Mueller-Guerre L, Marjon NA, Gut A, Minotti R, Meyer MR, Amann K, Ammann E, Perez-Dominguez A, Genoni M, Clegg DJ, Dun NJ, Resta TC, Prossnitz ER, Barton M. Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ Res. 2009;104: 288-291.
14. Michael SK, Surks HK, Wang Y, Zhu Y, Blanton R, Jamnongjit M, Aronovitz M, Baur W, Ohtani K, Wilkerson MK, Bonev AD, Nelson MT, Karas RH, Mendelsohn ME. High blood pressure arising from a defect in vascular function. Proc Natl Acad Sci US A. 2008;105:6702-6707. (Pubitemid 351754570)
15. Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and non-muscle myosin II: modulated by G proteins, kinases, and myosin phos-phatase. Physiol Rev. 2003;83:1325-1358. (Pubitemid 37222274)
16. Sward K, Dreja K, Susnjar M, Hellstrand P, Hartshorne DJ, Walsh MP. Inhibition of Rho-associated kinase blocks agonist-induced Ca2 + sensi-tization of myosin phosphorylation and force in guinea-pig ileum. J Physiol. 2000;522:33-49. (Pubitemid 30061356)
17. Wettschureck N, Offermanns S. Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med. 2002;80:629-638. (Pubitemid 35471727)
18. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science. 1996;273:245-248. (Pubitemid 26285892)
19. Bishop AL, Hall A. Rho GTPases and their effector proteins. Biochem J. 2000;348:241-255. (Pubitemid 30345195)
20. McVeigh GE, Plumb R, Hughes S. Vascular abnormalities in Hypertension: cause, effect, or therapeutic target? Curr Hypertens Rep. 2004; 6:171-176. (Pubitemid 39359558)
21. Horman S, Morel N, Vertommen D, Hussain N, Neumann D, Beauloye C El Najjar N, Forcet C, Viollet B, Walsh MP, Hue L, Rider MH. AMP-activated protein kinase phosphorylates and desensitizes smooth muscle myosin light chain kinase. J Biol Chem. 2008;283:18505-18512.
22. Fordjour AK, Harrington EO. PKCσ influences p190 phosphorylation and activity: events independent of PKCσ-mediated regulation of endothelial cell stress fiber and focal adhesion formation and barrier function. Biochim Biophys Acta. 2009;1790:1179-1190.
23. Wang S, Dale GL, Song P, Viollet B, Zou MH. AMPKα1 deletion shortens erythrocyte life span in mice: role of oxidative stress. J Biol Chem. 2010;285:19976-19985.
24. Foretz M, Hebrard S, Guihard S, Leclerc J, Do Cruzeiro M, Hamard G, Niedergang F, Gaudry M, Viollet B. The AMPKγ1 subunit plays an essential role in erythrocyte membrane elasticity, and its genetic inacti-vation induces splenomegaly and anemia. FASEB J. 2011;25:337-347.
25. Noma K, Rikitake Y, Oyama N, Yan G, Alcaide P, Liu PY, Wang H, Ahl D, Sawada N, Okamoto R, Hiroi Y, Shimizu K, Luscinskas FW, Sun J, Liao JK. ROCK1 mediates leukocyte recruitment and neointima for-mation following vascular injury. J Clin Invest. 2008;118:1632-1644. (Pubitemid 351632368)
26. Kroll J, Epting D, Kern K, Dietz CT, Feng Y, Hammes HP, Wieland T, Augustin HG. Inhibition of Rho-dependent kinases ROCK I/II activates VEGF-driven retinal neovascularization and sprouting angiogenesis. Am J Physiol Heart Circ Physiol. 2009;296:H893-H899.
27. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T. Acti-vation of AMP kinase and inhibition of Rho kinase induce the mineral-ization of osteoblastic MC3T3-E1 cells through endothelial NOS and BMP-2 expression. Am J Physiol Endocrinol Metab. 2009;296: E139-E146.
28. Miranda L, Carpentier S, Platek A, Hussain N, Gueuning MA, Ver-tommen D, Ozkan Y, Sid B, Hue L, Courtoy PJ, Rider MH, Horman S. AMP-activated protein kinase induces actin cytoskeleton reorganization in epithelial cells. Biochem Biophys Res Commun. 396:656-661.
29. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res. 2006;98:322-334.
30. Shin SM, Cho IJ, Kim SG. Resveratrol protects mitochondria against oxidative stress through AMP-activated protein kinase-mediated glycogen synthase kinase-3/3 inhibition downstream of poly(ADP-ribose)polymerase-LKB1 pathway. Mol Pharmacol. 2009;76:884-895.
31. Xu J, Zou MH. Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation. 2009;120:1266-1286.
32. Rodriguez A, Catalan V, Becerril S, Gil MJ, Mugueta C, Gomez-Ambrosi J, Fruhbeck G. Impaired adiponectin-AMPK signalling in insulin-sensitive tissues of hypertensive rats. Life Sci. 2008;83:540-549.
33. Kim JE, Choi HC. Losartan inhibits vascular smooth muscle cell prolif-eration through activation of AMP-activated protein kinase. Korean J Physiol Pharmacol. 2010;14:299-304.
34. Yoshida D, Higashiura K, Shinshi Y, Satoh K, Hyakkoku M, Yoshida H, Miyazaki Y, Ura N, Shimamoto K. Effects of angiotensin II receptor blockade on glucose metabolism via AMP-activated protein kinase in insulin-resistant hypertensive rats. JAm Soc Hypertens. 2009;3:3-8.